Abstract
‘Triple negative’ breast cancer (TNBC; oestrogen (ER), progesterone (PR), and HER2 receptor negative) is an aggressive form of breast cancer (BC) with a poor prognosis. TNBC patients cannot benefit from treatment based on ER, PR, and HER2 status. Therefore, other markers are sought. TOP2A gene amplification is considered an anthracycline treatment response predictor and TOP2A aberrations (amplifications, deletions) are found in HER2 amplified BC. Recently, TOP2A amplification has also been described in HER2 non-amplified BC.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
